Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2020 | Treating relapsing-remitting MS aggressively at disease presentation

Abhijit Chaudhuri • 21 Oct 2020
CONy 2020
Multiple Sclerosis and Related Disorders

Abhijit Chaudhuri, DM, MD, PhD, FACP, FRCP, FEAN, Queen’s Hospital, Romford, UK, discusses the benefits of aggressively treating relapsing-remitting multiple sclerosis (MS) at presentation. With traditional therapeutic strategies, patients do not receive high efficacy treatments until 2 to 3 years after disease presentation. By this point, there is little prospect for function recovery. Therefore, high efficacy treatment options should not be delayed and be an available option at presentation. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.

Disclosures

Abhijit Chaudhuri has received travel grants, honoraria and speaker fee from Merck, Bial and Eisai in the past two years.

More from Abhijit Chaudhuri

Changes in the MS treatment landscape over the last 2 years
6:03
Changes in the MS treatment landscape over the last 2 years
Abhijit Chaudhuri • 22 Mar 2022
Patients with new onset psychosis should receive corticosteroids to treat autoimmune encephalitis
5:33
Patients with new onset psychosis should receive corticosteroids to treat autoimmune encephalitis
Abhijit Chaudhuri • 22 Mar 2022
Controversies in treating NMOSD and MOGAD
1:54
Controversies in treating NMOSD and MOGAD
Abhijit Chaudhuri • 22 Mar 2022
MS: challenges and the impact of a healthy lifestyle
2:16
MS: challenges and the impact of a healthy lifestyle
Abhijit Chaudhuri • 21 Oct 2020

Related Videos

What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
6:48
What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
Mar Tintoré • 3 Jul 2026
Ovarian aging and long-term prognosis in women with multiple sclerosis
3:07
Ovarian aging and long-term prognosis in women with multiple sclerosis
Mar Tintoré • 3 Jul 2026
The emerging role of AI in the diagnosis and management of multiple sclerosis
1:55
The emerging role of AI in the diagnosis and management of multiple sclerosis
Celia Oreja-Guevara • 29 Jun 2026
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
3:15
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
Franz Felix Konen • 28 Jul 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals